Proteomics Market size is estimated to be valued at USD 20,869.2 million in 2021 and is poised to grow at a CAGR of 12.5% over 2022-2028. Proteomics is a technique for identifying and studying proteins implicated in diseases, as well as their expression, activity, and structure. Proteomic research may also be utilized to find prognostic indicators and diagnose cancer, infectious illnesses, malaria, and TB. In the pharmaceutical sector, proteomics is utilized to examine the mechanism of medication action or toxicity. Based on the technology protein microarray segment generated the highest revenue in 2021 in the proteomics market, owing to the technology being widely used to track protein interactions in less time than other technologies. Furthermore, this procedure is required lesser time and is cost-effective. The entire information about DNA/RNA binding proteins can be made available with the use of a protein microarray. Moreover, based on components, the reagents segment accounted for the majority of proteomics market share, it is attributed to the availability of a wide range of reagents and the need for reliable, specific, and fast detection of diseases at the early stages as they are extensively utilized in primary screening in drug discovery and microarray technologies. Increasing demand for factors like rising demand for personalized medicine, increasing R&D expenditure, government funding for proteomics, and technological advancements driving the market growth over the forecast years.
Recent Market Developments:
In Feb 2021, Agilent Technologies Inc. launched Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit intended for the qualitative detection of immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum or plasma.